EX-4.2



 





EXHIBIT 4.2





NEITHER THESE SECURITIES NOR THE SECURITIES FOR WHICH THESE SECURITIES ARE EXERCISABLE HAVE
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, TRANSFERRED,
ASSIGNED OR HYPOTHECATED UNLESS THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT
COVERING SUCH SECURITIES, THE SALE IS MADE IN ACCORDANCE WITH RULE 144 UNDER SUCH ACT OR THE ISSUER
RECEIVES AN OPINION OF COUNSEL FOR THE HOLDER OF THESE SECURITIES REASONABLY SATISFACTORY TO THE
ISSUER, STATING THAT SUCH SALE, TRANSFER, ASSIGNMENT OR HYPOTHECATION IS EXEMPT FROM THE
REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SUCH ACTS.




BTHC VI, INC.




FORM OF WARRANT




			
	 	 	 
	Warrant No. [___]
	 	Dated: [_______], 2007






     BTHC VI, Inc., a Delaware corporation (the “Company”), hereby certifies that, for value
received, __________________ [Name of Holder] or its registered assigns (the “Holder”), is entitled to
purchase from the Company up to a total of [_____]1 shares of common stock, $0.001 par
value per share (the “Common Stock”), of the Company (each such share, a “Warrant Share” and all
such shares issuable under the warrants, the “Warrant Shares”) at an exercise price equal to $6.00
per share (as adjusted from time to time as provided in Section 9, the “Exercise Price”), at any
time and from the date hereof and through and including the date that is five (5) years from the
date of issuance hereof (the “Expiration Date”), and subject to the following terms and conditions.
This Warrant (“Warrant”) is one of a series of similar warrants issued pursuant to that certain
Securities Purchase Agreement, dated as of [______], 2007, by and among the Company, Athersys,
Inc. and the Investors identified therein (the “Purchase Agreement”). All such warrants are
referred to herein, collectively, as the “Warrants” and the holders thereof along with the Holder
named herein, the “Holders.”



     1. Definitions. In addition to the terms defined elsewhere in this Warrant,
capitalized terms that are not otherwise defined herein have the meanings given to such terms in
the Purchase Agreement.



     2. Registration of Warrant. The Company shall register this Warrant, upon records to
be maintained by the Company for that purpose (the “Warrant Register”), in the name of the record
Holder hereof from time to time. The Company may deem and treat the registered Holder of this
Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to
the Holder, and for all other purposes, absent actual notice to the contrary.



     3. Registration of Transfers. The Company shall register the transfer of any portion
of this Warrant in the Warrant Register, upon surrender of this Warrant, with the Form of
Assignment attached hereto duly completed and signed, to the Transfer Agent or to the Company





 




			
	1	 	25% warrant coverage




1









 









at its address specified herein. Upon any such registration or transfer, a new warrant to
purchase Common Stock, in substantially the form of this Warrant (any such new warrant, a “New
Warrant”), evidencing the portion of this Warrant so transferred shall be issued to the transferee
and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any,
shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee
thereof shall be deemed the acceptance by such transferee of all of the rights and obligations of a
holder of a Warrant.




     4. Exercise and Duration of Warrants.



          (a) This Warrant shall be exercisable by the registered Holder at any time and from time to
time on or after the date hereof to and including the Expiration Date. At 6:30 P.M., New York City
time on the Expiration Date, the portion of this Warrant not exercised prior thereto shall be and
become void and of no value; provided that, if the average of the Closing Prices for the five
Trading Days immediately prior to (but not including) the Expiration Date exceeds the Exercise
Price on the Expiration Date, provided further that, if on the Expiration Date, there is no
effective Registration Statement covering the resale of the Warrant Shares, or no current
prospectus under such Registration Statement is available, then this Warrant shall be deemed to
have been exercised in full (to the extent not previously exercised) on a “cashless exercise” basis
at 6:30 P.M. New York City time on the Expiration Date. A “cashless exercise” means that in lieu
of paying the aggregate purchase price for the shares being purchased upon exercise of the Warrants
in cash, the Holder will forfeit a number of shares underlying the Warrants pursuant to Section
10 below.




          (b) A Holder may exercise this Warrant by delivering to the Company (i) an exercise notice, in
the form attached hereto (the “Exercise Notice”), appropriately completed and duly signed, and (ii)
payment of the Exercise Price for the number of Warrant Shares as to which this Warrant is being
exercised (which may take the form of a “cashless exercise” if so indicated in the Exercise Notice
pursuant to Section 10 below), and the date such items are delivered to the Company (as determined
in accordance with the notice provisions hereof) is an “Exercise Date.” The Holder shall not be
required to deliver the original Warrant in order to effect an exercise hereunder. Execution and
delivery of the Exercise Notice shall have the same effect as cancellation of the original Warrant
and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant
Shares.




          (c) Exercise Disputes. In the case of any dispute with respect to the number of
shares to be issued upon exercise of this Warrant, the Company shall promptly issue such number of
shares of Common Stock that is not disputed and shall submit the disputed determinations or
arithmetic calculations to the Holder via facsimile within two (2) Business Days of receipt of the
Holder’s election to purchase Warrant Shares. If the Holder and the Company are unable to agree as
to the determination of the Purchase Price within two (2) Business Days of such disputed
determination or arithmetic calculation being submitted to the Holder, then the Company shall in
accordance with this Section, submit via facsimile the disputed determination to an independent
reputable accounting firm of national standing, selected jointly by the Company and the Holder.
The Company shall cause such accounting firm to perform the determinations or calculations and
notify the Company and the Holder of the results within forty-eight (48) hours from the time it
receives the disputed determinations of




2









 







calculations. Such accounting firm’s determination shall be binding upon all parties absent
manifest error. The Company shall then on the next Business Day issue certificate(s) representing
the appropriate number of Warrant Shares of Common Stock in accordance with such accounting firm’s
determination and this Section. The prevailing party shall be entitled to reimbursement of all
fees and expenses of such determination and calculation.




     5. Delivery of Warrant Shares.



          (a) Upon exercise of this Warrant, the Company shall promptly (but in no event later than
three Trading Days after the Exercise Date) issue or cause to be issued and cause to be delivered
to or upon the written order of the Holder and in such name or names as the Holder may designate, a
certificate for the Warrant Shares issuable upon such exercise, free of restrictive legends unless
a registration statement covering the resale of the Warrant Shares and naming the Holder as a
selling stockholder thereunder is not then effective and the Warrant Shares are not freely
transferable without volume restrictions pursuant to Rule 144 under the Securities Act of 1933, as
amended. The Holder, or any Person so designated by the Holder to receive Warrant Shares, shall be
deemed to have become holder of record of such Warrant Shares as of the Exercise Date. The Company
shall, upon request of the Holder, use its best efforts to deliver Warrant Shares hereunder
electronically through the Depository Trust Corporation or another established clearing corporation
performing similar functions.




          (b) This Warrant is exercisable, either in its entirety or, from time to time, for a portion
of the number of Warrant Shares. Upon surrender of this Warrant following one or more partial
exercises, the Company shall issue or cause to be issued, at its expense, a New Warrant evidencing
the right to purchase the remaining number of Warrant Shares.




          (c) In addition to any other rights available to a Holder, if the Company fails to deliver to
the Holder a certificate representing Warrant Shares by the third Trading Day after the date on
which delivery of such certificate is required by this Warrant, and if after such third Trading Day
the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver
in satisfaction of a sale by the Holder of the Warrant Shares that the Holder anticipated receiving
from the Company (a “Buy-In”), then the Company shall, within three Trading Days after the Holder’s
request and in the Holder’s discretion, either (i) pay cash to the Holder in an amount equal to the
Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common
Stock so purchased (the “Buy-In Price”), at which point the Company’s obligation to deliver such
certificate (and to issue such Common Stock) shall terminate, or (ii) promptly honor its obligation
to deliver to the Holder a certificate or certificates representing such Common Stock and pay cash
to the Holder in an amount equal to the excess (if any) of the Buy-In Price over the product of (A)
such number of shares of Common Stock, times (B) the Closing Price on the date of the event giving
rise to the Company’s obligation to deliver such certificate.




          (d) The Company’s obligations to issue and deliver Warrant Shares in accordance with the terms
hereof are absolute and unconditional, irrespective of any action or inaction by the Holder to
enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any
judgment against any Person or any action to enforce the same, or any setoff, counterclaim,
recoupment, limitation or termination, or any breach or alleged breach




3









 







by the Holder or any other Person of any obligation to the Company or any violation or alleged
violation of law by the Holder or any other Person, and irrespective of any other circumstance
which might otherwise limit such obligation of the Company to the Holder in connection with the
issuance of Warrant Shares. Nothing herein shall limit a Holder’s right to pursue any other
remedies available to it hereunder, at law or in equity including, without limitation, a decree of
specific performance and/or injunctive relief with respect to the Company’s failure to timely
deliver certificates representing shares of Common Stock upon exercise of the Warrant as required
pursuant to the terms hereof.




     6. Charges, Taxes and Expenses. Issuance and delivery of certificates for shares of
Common Stock upon exercise of this Warrant shall be made without charge to the Holder for any issue
or transfer tax, withholding tax, transfer agent fee or other incidental tax or expense in respect
of the issuance of such certificates, all of which taxes and expenses shall be paid by the Company;
provided, however, that the Company shall not be required to pay any tax which may be payable in
respect of any transfer involved in the registration of any certificates for Warrant Shares or
Warrants in a name other than that of the Holder. The Holder shall be responsible for all other
tax liability that may arise as a result of holding or transferring this Warrant or receiving
Warrant Shares upon exercise hereof.



     7. Replacement of Warrant. If this Warrant is mutilated, lost, stolen or destroyed,
the Company shall issue or cause to be issued in exchange and substitution for and upon
cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon
receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction and
customary and reasonable bond or indemnity, if requested. Applicants for a New Warrant under such
circumstances shall also comply with such other reasonable regulations and procedures and pay such
other reasonable third-party costs as the Company may prescribe.



     8. Reservation of Warrant Shares. The Company covenants that it will at all times
reserve and keep available out of the aggregate of its authorized but unissued and otherwise
unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon
exercise of this Warrant as herein provided, 100% of the number of Warrant Shares which are then
issuable and deliverable upon the exercise of this entire Warrant, free from preemptive rights or
any other contingent purchase rights of persons other than the Holder (after giving effect to the
adjustments and restrictions of Section 9, if any). The Company covenants that all Warrant
Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise
Price in accordance with the terms hereof, be duly and validly authorized, issued and fully paid
and nonassessable. The Company will take all such action as may be necessary to assure that such
shares of Common Stock may be issued as provided herein without violation of any applicable law or
regulation, or of any requirements of any securities exchange or automated quotation system upon
which the Common Stock may be listed.



     9. Certain Adjustments. The Exercise Price and number of Warrant Shares issuable upon
exercise of this Warrant are subject to adjustment from time to time as set forth in this
Section 9.



          (a) Stock Dividends and Splits. If the Company, at any time while this Warrant is
outstanding, (i) pays a stock dividend on its Common Stock or otherwise makes a



4









 







distribution on any class of capital stock that is payable in shares of Common Stock, (ii)
subdivides outstanding shares of Common Stock into a larger number of shares, or (iii) combines
outstanding shares of Common Stock into a smaller number of shares, then in each such case the
Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of
shares of Common Stock outstanding immediately before such event and of which the denominator shall
be the number of shares of Common Stock outstanding immediately after such event. Any adjustment
made pursuant to clause (i) of this paragraph shall become effective immediately after the record
date for the determination of stockholders entitled to receive such dividend or distribution, and
any adjustment pursuant to clause (ii) or (iii) of this paragraph shall become effective
immediately after the effective date of such subdivision or combination.



          (b) Distributions Made Prior to Exercise. If the Company, at any time while this
Warrant is outstanding, distributes to holders of Common Stock (i) evidences of its indebtedness,
(ii) any security (other than a distribution of Common Stock covered by Section 9(a)), (iii) rights
or warrants to subscribe for or purchase any security, or (iv) any other asset (in each case, a
“Distribution”), then in each such case any Exercise Price in effect immediately prior to the close
of business on the record date fixed for the determination of holders of Common Stock entitled to
receive the Distribution shall be reduced, effective as of the close of business on such record
date, to a price determined by multiplying such Exercise Price by a fraction of which (i) the
numerator shall be the Weighted Average Price2 of the Common Stock on the Trading Day
immediately preceding such record date minus the value of the Distribution (as determined in good
faith by the Company’s Board of Directors) applicable to one share of Common Stock, and (ii) the
denominator shall be the Weighted Average Price of the Common Stock on the Trading Day immediately
preceding such record date.




          (c) Notwithstanding the provisions set forth in Section 9(b) above, if the Company, at
any time while this Warrant is outstanding, makes a Distribution to the holders of Common Stock,
then in each such case the Holder shall have the option to receive such Distribution which would
have been made to the Holder had such Holder been the holder of such Warrant Shares on the record
date for the determination of stockholders entitled to such Distribution; provided, however, if the
Holder elects to receive such Distribution, it will not be entitled to receive the adjustment to
the Exercise Price specified in clause (b) above.




          (d) Fundamental Transactions. If, at any time while this Warrant is outstanding, (i)
the Company effects any merger or consolidation of the Company with or into






 




			
	2	 	“Weighted Average Price” means, for any security as of any date, the dollar volume-weighted average
price for such security on NASDAQ during the period beginning at 9:30:01 a.m.,
New York Time (or such other time as NASDAQ publicly announces is the official
open of trading), and ending at 4:00:00 p.m., New York Time (or such other time
as NASDAQ publicly announces is the official close of trading) as reported by
Bloomberg (means Bloomberg Financial Markets) through its “Volume at
Price” functions, or, if the foregoing does not apply, the dollar
volume-weighted average price of such security in the over-the-counter market
on the electronic bulletin board for such security during the period beginning
at 9:30:01 a.m., New York Time (or such other time as such Principal Market
publicly announces is the official open of trading), and ending at 4:00:00
p.m., New York Time (or such other time as such market publicly announces is
the official close of trading) as reported by Bloomberg, if no dollar
volume-weighted average price is reported for such security by Bloomberg for
such hours, the average of the highest closing bid price and the lowest closing
ask price of any of the market makers for such security as reported in the
“pink sheets” by Pink Sheets LLC (formerly the National Quotation
Bureau, Inc.). If the Weighted Average Price cannot be calculated for a
security on a particular date on any of the foregoing bases, the Weighted
Average Price of such security on such date shall be the fair market value as
mutually determined by the Company in good faith. All such determinations
shall be appropriately adjusted for any share dividend, share split, share
combination or other similar transaction during the applicable calculation
period.




5









 









(whether or not the Company is the surviving corporation) another Person, (ii) the Company
effects any sale, assignment, transfer, conveyance or other disposition of all or substantially all
of its assets in one or a series of related transactions; provided, however, that for avoidance of
doubt, the granting of a lien on all or substantially all of the Company’s assets as collateral
shall not be deemed a Fundamental Transaction hereunder, (iii) the Company allows another Person to
make a purchase, tender or exchange offer that is accepted by the holders of more than the 50% of
either the outstanding shares of Common Stock (not including any shares of Common Stock held by the
Person or Persons making or party to, or associated or affiliated with the Persons making or party
to, such purchase, tender or exchange offer), (iv) the Company consummates a stock purchase
agreement or other business combination (including, without limitation, a reorganization,
recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person
acquires more than the 50% of the outstanding shares of Common Stock (not including any shares of
Common Stock held by the other Person or other Persons making or party to, or associated or
affiliated with the other Persons making or party to, such stock purchase agreement or other
business combination), or (v) the Company effects any reclassification of the Common Stock or any
compulsory share exchange pursuant to which the Common Stock is effectively converted into or
exchanged for other securities, cash or property (other than as a result of a subdivision or
combination of shares of Common Stock covered by Section 9(a) above) (in any such case, a
“Fundamental Transaction”), then the Company shall use its reasonable best efforts to ensure that
lawful and adequate provision shall be made whereby each Holder shall thereafter continue to have
the right to purchase and receive upon the basis and upon the terms and conditions herein specified
and in lieu of the Warrant Shares issuable upon exercise of the Warrants held by such Holder,
shares of capital stock or similar equity interests (“Acquirer Shares”) in the surviving or
acquiring entity (“Acquirer”), as the case may be, such that the aggregate value of the Holder’s
warrants to purchase such number of Acquirer Shares, where the value of each new warrant to
purchase one Acquirer Share is determined in accordance with the Black-Scholes Option Pricing
formula set forth in Exhibit A hereto, is equivalent to the aggregate value of the Warrants held by
such Holder, where the value of each Warrant to purchase one share in the Company is determined in
accordance with the Black-Scholes Option Pricing formula set forth Exhibit B hereto. Furthermore,
the new warrants to purchase Acquirer Shares referred to herein shall have the same expiration date
as the Warrants, and shall have a strike price, KAcq, that is calculated in accordance with Exhibit
A hereto. Moreover, appropriate provision shall be made with respect to the rights and interests
of each Holder to the end that the provisions hereof (including, without limitation, provision for
adjustment of the Exercise Price) shall thereafter be applicable, as nearly equivalent as may be
practicable in relation to any Acquirer Shares thereafter deliverable upon the exercise thereof.
The provisions of this Section 9(d) shall similarly apply to successive Fundamental
Transactions. If the Company, in spite of using its reasonable best efforts, is unable to cause
these Warrants to continue in full force and effect until the Expiration Date in connection with
any Fundamental Transaction, then the Company shall pay the Holders in cash an amount per Warrant
to purchase one share of Common Stock in the Company that is calculated in accordance with the
Black-Scholes Option Pricing formula set forth in Exhibit B hereto.




          (e) Number of Warrant Shares. Simultaneously with any adjustment to the Exercise
Price pursuant to paragraph (a) of this Section, the number of Warrant Shares that may be purchased
upon exercise of this Warrant shall be increased or decreased proportionately, as



6









 







applicable, so that after such adjustment the aggregate Exercise Price payable hereunder for
the increased or decreased, as applicable, number of Warrant Shares shall be the same as the
aggregate Exercise Price in effect immediately prior to such adjustment.



          (f) Calculations. All calculations under this Section 9 shall be made to the
nearest cent or the nearest 1/100th of a share, as applicable. The number of shares of Common
Stock outstanding at any given time shall not include shares owned or held by or for the account of
the Company, and the disposition of any such shares shall be considered an issue or sale of Common
Stock.




          (g) Notice of Adjustments. Upon the occurrence of each adjustment pursuant to this
Section 9, the Company at its expense will promptly compute such adjustment in accordance
with the terms of this Warrant and prepare a certificate setting forth such adjustment, including a
statement of the adjusted Exercise Price and adjusted number or type of Warrant Shares or other
securities issuable upon exercise of this Warrant (as applicable), describing the transactions
giving rise to such adjustments and showing in detail the facts upon which such adjustment is
based. Upon written request, the Company will promptly deliver a copy of each such certificate to
the Holder and to the Company’s Transfer Agent.




          (h) Notice of Corporate Events. If the Company (i) declares a dividend or any other
distribution of cash, securities or other property in respect of its Common Stock, including
without limitation any granting of rights or warrants to subscribe for or purchase any capital
stock of the Company or any Subsidiary, (ii) authorizes or approves, enters into any agreement
contemplating or solicits stockholder approval for any Fundamental Transaction or (iii) authorizes
the voluntary dissolution, liquidation or winding up of the affairs of the Company, then the
Company shall deliver to the Holder a notice describing the material terms and conditions of such
transaction, at least ten calendar days prior to the applicable record or effective date on which a
Person would need to hold Common Stock in order to participate in or vote with respect to such
transaction, and the Company will take all steps reasonably necessary in order to insure that the
Holder is given the practical opportunity to exercise this Warrant prior to such time so as to
participate in or vote with respect to such transaction; provided, however, that the failure to
deliver such notice or any defect therein shall not affect the validity of the corporate action
required to be described in such notice.




     10. Payment of Exercise Price. The Holder shall either (i) pay the Exercise Price in
immediately available funds (a “cash exercise”) or (ii) satisfy its obligation to pay the Exercise
Price through a “cashless exercise,” in which event the Company shall issue to the Holder the
number of Warrant Shares determined as follows:



	 	 	 
	 

	 	X = Y [(A-B)/A]
	where:
	 	 
	 

	 	X = the number of Warrant Shares to be issued to the Holder.
	 
	 	 
	 

	 	Y = the number of Warrant Shares with respect to which this Warrant
is being exercised (prior to cashless exercise).
	 
	 	 
	 

	 	A = the average of the Closing Prices for the five Trading Days






7









 






	 	 	 
	 

	 	immediately prior to (but not including) the Exercise Date.
	 
	 	 
	 

	 	B = the Exercise Price.






          For purposes of Rule 144 promulgated under the Securities Act, it is intended, understood and
acknowledged that the Warrant Shares issued in a cashless exercise transaction shall be deemed to
have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to
have commenced, on the date this Warrant was originally issued pursuant to the Purchase Agreement.




     11. Fractional Shares. The Company shall not be required to issue or cause to be
issued fractional Warrant Shares on the exercise of this Warrant. If any fraction of a Warrant
Share would, except for the provisions of this Section, be issuable upon exercise of this Warrant,
the number of Warrant Shares to be issued will be rounded up to the nearest whole share.



     12. Notices. Any and all notices or other communications or deliveries hereunder
(including without limitation any Exercise Notice) shall be in writing and shall be deemed given
and effective on the earliest of (i) the date of transmission, if such notice or communication is
delivered via facsimile at the facsimile number specified in the Purchase Agreement prior to 6:30
p.m. (New York City time) on a Trading Day, (ii) the next Trading Day after the date of
transmission, if such notice or communication is delivered via facsimile at the facsimile number
specified in the Purchase Agreement on a day that is not a Trading Day or later than 6:30 p.m. (New
York City time) on any Trading Day, (iii) the Trading Day following the date of mailing, if sent by
nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom
such notice is required to be given. The address for such notices or communications shall be as
set forth in the Purchase Agreement.



     13. Warrant Agent. The Company shall serve as warrant agent under this Warrant. Upon
30 days’ notice to the Holder, the Company may appoint a new warrant agent. Any corporation into
which the Company or any new warrant agent may be merged or any corporation resulting from any
consolidation to which the Company or any new warrant agent shall be a party or any corporation to
which the Company or any new warrant agent transfers substantially all of its corporate trust or
stockholders services business shall be a successor warrant agent under this Warrant without any
further act. Any such successor warrant agent shall promptly cause notice of its succession as
warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder’s
last address as shown on the Warrant Register.



     14. Registration of Warrant Shares. The Warrant Shares shall be entitled to
registration rights as set forth in the Purchase Agreement pursuant to which this Warrant was
issued.



     15. Miscellaneous.



          (a) Subject to the restrictions on transfer set forth on the first page hereof, this Warrant
may be assigned by the Holder. This Warrant may not be assigned by the Company, except to a
successor in the event of a Fundamental Transaction. This Warrant shall be binding on and inure to
the benefit of the parties hereto and their respective successors and assigns.




8









 







Subject to the preceding sentence, nothing in this Warrant shall be construed to give to any
Person other than the Company and the Holder any legal or equitable right, remedy or cause of
action under this Warrant.




          (b) The Company will not, by amendment of its governing documents or through any
reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities
or any other voluntary action, seek to call or redeem this Warrant or avoid or seek to avoid the
observance or performance of any of the terms of this Warrant, but will at all times in good faith
assist in the carrying out of all such terms and in the taking of all such action as may be
necessary or appropriate in order to protect the rights of the Holder against dilution or other
impairment. Without limiting the generality of the foregoing, the Company (i) will not increase
the par value of any Warrant Shares above the amount payable therefor on such exercise, (ii) will
take all such action as may be reasonably necessary or appropriate in order that the Company may
validly and legally issue fully paid and nonassessable Warrant Shares, free from all taxes, liens,
security interests, encumbrances, preemptive or similar rights and charges of stockholders (other
than those imposed by the Investors), on the exercise of the Warrant, and (iii) will not close its
stockholder books or records in any manner which interferes with the timely exercise of this
Warrant.




          (c) Remedies; Specific Performance. The Company acknowledges and agrees that there
would be no adequate remedy at law to the Holder of this Warrant in the event of any default or
threatened default by the Company in the performance of or compliance with any of the terms of this
Warrant and accordingly, the Company agrees that, in addition to any other remedy to which the
Holder may be entitled at law or in equity, the Holder shall be entitled to seek to compel specific
performance of the obligations of the Company under this Warrant, without the posting of any bond,
in accordance with the terms and conditions of this Warrant in any court of the United States or
any State thereof having jurisdiction, and if any action should be brought in equity to enforce any
of the provisions of this Warrant, the Company shall not raise the defense that there is an
adequate remedy at law. Except as otherwise provided by law, a delay or omission by the Holder
hereof in exercising any right or remedy accruing upon any such breach shall not impair the right
or remedy or constitute a waiver of or acquiescence in any such breach. No remedy shall be
exclusive of any other remedy. All available remedies shall be cumulative.




          (d) Amendments and Waivers. The Company may, without the consent of the Holders, by
supplemental agreement or otherwise, (i) make any changes or corrections in this Agreement that are
required to cure any ambiguity or to correct or supplement any provision herein which may be
defective or inconsistent with any other provision herein or (ii) add to the covenants and
agreements of the Company for the benefit of the Holders (including, without limitation, reduce the
Exercise Price or extend the Expiration Date), or surrender any rights or power reserved to or
conferred upon the Company in this Agreement; provided that, in the case of (i) or (ii), such
changes or corrections shall not adversely affect the interests of Holders of then outstanding
Warrants in any material respect. This Warrant may also be amended or waived with the consent of
the Company and the Holder. Further, the Company may, with the consent, in writing or at a
meeting, of the Holders (the “Required Holders”) of the then outstanding Warrants exercisable for
two-thirds (2/3) or greater of the Common Stock eligible under such Warrants, amend in any way, by
supplemental agreement or otherwise, this Warrant




9









 







and/or all of the outstanding Warrants; provided, however, that (i) no such amendment by its
express terms shall adversely affect any Holder differently than it affects all other Holders,
unless such Holder consents thereto, and (ii) no such amendment concerning the number of Warrant
Shares or Exercise Price shall be made unless any Holder who will be affected by such amendment
consents thereto. If a new warrant agent is appointed by the Company, it shall at the request of
the Company, and without need of independent inquiry as to whether such supplemental agreement is
permitted by the terms of this Section 15(d), join with the Company in the execution and
delivery of any such supplemental agreements, but shall not be required to join in such execution
and delivery for such supplemental agreement to become effective.




          (e) GOVERNING LAW; VENUE; WAIVER OF JURY TRIAL. THE CORPORATE LAWS OF THE STATE OF
NEW YORK SHALL GOVERN ALL ISSUES CONCERNING THE RELATIVE RIGHTS OF THE COMPANY AND ITS
STOCKHOLDERS. ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION
OF THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF
THE STATE OF NEW YORK. THE COMPANY AND INVESTORS HEREBY IRREVOCABLY SUBMIT TO THE EXCLUSIVE
JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN
FOR THE ADJUDICATION OF ANY DISPUTE BROUGHT BY THE COMPANY OR ANY INVESTOR HEREUNDER, IN CONNECTION
HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN, AND HEREBY IRREVOCABLY
WAIVE, AND AGREE NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING BROUGHT BY THE COMPANY OR ANY
INVESTOR, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT, OR
THAT SUCH SUIT, ACTION OR PROCEEDING IS IMPROPER. EACH PARTY HEREBY IRREVOCABLY WAIVES PERSONAL
SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY
MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF
DELIVERY) TO SUCH PARTY AT THE ADDRESS IN EFFECT FOR NOTICES TO IT UNDER THIS AGREEMENT AND AGREES
THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF.
NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY
MANNER PERMITTED BY LAW. THE COMPANY AND INVESTORS HEREBY WAIVE ALL RIGHTS TO A TRIAL BY JURY.




          (f) The headings herein are for convenience only, do not constitute a part of this Warrant and
shall not be deemed to limit or affect any of the provisions hereof.




          (g) In case any one or more of the provisions of this Warrant shall be invalid or
unenforceable in any respect, the validity and enforceability of the remaining terms and provisions
of this Warrant shall not in any way be affected or impaired thereby and the parties will attempt
in good faith to agree upon a valid and enforceable provision which shall be a commercially
reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision
in this Warrant.




10









 








     IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized
officer as of the date first indicated above.



	 	 	 	 	 
	 	BTHC VI, INC.

 	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 



 









 






	 	 	 	 	 



FORM OF EXERCISE NOTICE



(To be executed by the Holder to exercise the right to purchase shares of Common Stock under the
foregoing Warrant)




To: BTHC VI, INC.



The undersigned is the Holder of Warrant No. ________ (the “Warrant”) issued by BTHC VI, Inc., a
Delaware corporation (the “Company”). Capitalized terms used herein and not otherwise defined have
the respective meanings set forth in the Warrant.





	 	(a)	 	The Warrant is currently exercisable to purchase a total of ______________
Warrant Shares.
	 
	 	(b)	 	The undersigned Holder hereby exercises its right to purchase _____________
Warrant Shares pursuant to the Warrant.
	 
	 	(c)	 	The Holder shall make Payment of the Exercise Price as follows (check one):
	 
	 	 	 	     o      “Cash Exercise” under Section 10
	 
	 	 	 	     o      “Cashless Exercise” under Section 10
	 
	 	(d)	 	If the holder is making a Cash Exercise, the holder shall pay the sum of
$________ to the Company in accordance with the terms of the Warrant.
	 
	 	(e)	 	Pursuant to this exercise, the Company shall deliver to the holder
________ Warrant Shares in accordance with the terms of the Warrant.
	 
	 	(f)	 	Following this exercise, the Warrant shall be exercisable to purchase a total
of ________ Warrant Shares.
	 
	 	(g)	 	Notwithstanding anything to the contrary contained herein, this Exercise Notice
shall constitute a representation by the Holder that, after giving effect to the
exercise provided for in this Exercise Notice, the Holder (together with its
affiliates) will not have beneficial ownership (together with the beneficial ownership
of such Person’s affiliates) of a number of shares of Common Stock which exceeds the
Maximum Percentage of the total outstanding shares of Common Stock as determined
pursuant to the provisions of Section 11(a) of the Warrant.





	 	 	 	 	 
	Dated: _____________, _____	Name of Holder:



(Print) _______________________________________

 	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 	 	(Signature must conform in all respects to name of holder as
specified on the face of the Warrant) 	 



 









 






	 	 	 	 	 



FORM OF ASSIGNMENT




[To be completed and signed only upon transfer of Warrant]





     FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers unto
________________ the right represented by the within Warrant to purchase ________ shares
of Common Stock of BTHC VI, Inc. to which the within Warrant relates and appoints _________________
attorney to transfer said right on the books of BTHC VI, Inc. with full power of substitution in
the premises.


Dated: ____________, ______




	 	 	 	 	 
	 	 	 
	 	 	 
	 	(Signature must conform in all respects to name of holder as specified on the face of the Warrant)


	 
	 	Address of Transferee 


	 
	 	 


	 
	 	 


	 
	 


In the presence of:



                                                                                




 









 





Exhibit A



Black Scholes Option Pricing formula to be used when calculating the value of each new warrant
to purchase one Acquirer Share shall be:



CAcq = SAcqe-λ(TAcq-tAcq)N(d1) — KAcqe-r(TAcq-tAcq)
N(d2), where



CAcq = value of each warrant to purchase one Acquirer Share



SAcq = price of one Acquirer Share as determined by reference to the average of the closing prices
on the securities exchange over the 20-day period ending three trading days prior to the closing of
the Fundamental Transaction described in Section 9(d) if the Acquirer Shares are then traded on
such exchange, or the average of the closing bid or sale prices (whichever is applicable) in the
over-the-counter market over the 20-day period ending three trading days prior to the closing of
the Fundamental Transaction if the Acquirer Shares are then actively traded in the over-the-counter
market, or the then most recently completed financing if the Acquirer Shares are not then traded on
a securities exchange or in the over-the-counter market



TAcq = expiration date of new warrants to purchase Acquirer Shares = TCorp



tAcq = date of issue of new warrants to purchase Acquirer Shares



TAcq-tAcq = time until warrant expiration, expressed in years



s = volatility = annualized standard deviation of daily log-returns (using a 262-day annualization
factor) of the price of Acquirer Shares on the securities exchange over a 20-day trading period,
determined by the Holders, that is within the 100-day trading period ending on the trading day
immediately after the public announcement of the Fundamental Transaction described in Section 9(d)
if the Acquirer Shares are then traded on such exchange, or the annualized standard deviation of
daily-log returns (using a 262-day annualization factor) of the closing bid or sale prices
(whichever is applicable) in the over-the-counter market over a 20-day trading period, determined
by the Holders, that is within the 100-day trading period ending on the trading day immediately
after the public announcement of the Fundamental Transaction if the Acquirer Shares are then
actively traded in the over-the-counter market, or 0.6 (or 60%) if the Acquirer Shares are not then
traded on a securities exchange or in the over-the-counter market.



N = cumulative normal distribution function



d1 = (ln(SAcq/KAcq) + (r-λ+s2/2)(TAcq-tAcq))
÷ (sv(TAcq-tAcq))



ln = natural logarithm



λ = dividend rate on the Acquirer Shares for the most recent 12-month period at the time of closing
of the Fundamental Transaction.



KAcq = strike price of new warrants to purchase Acquirer Shares = KCorp * (SAcq / SCorp)



r = annual yield, as reported by Bloomberg at time tAcq, of the United States Treasury security
measuring the nearest time TAcq



d2 = d1- sv(TAcq-tAcq)




 









 








Exhibit B



Black Scholes Option Pricing formula to be used when calculating the value of each Warrant to
purchase one share of Common Stock shall be:



CCorp = SCorpe-λ(TCorp-tCorp)N(d1) — KCorpe-
r(TCorp-tCorp)N(d2), where



CCorp = value of each Warrant to purchase one share of Common Stock



SCorp = price of Common Stock as determined by reference to the average of the closing prices on
the securities exchange over the 20-day period ending three trading days prior to the closing of
the Fundamental Transaction described in Section 9(d) if the Common Stock is then traded on such
exchange, or the average of the closing bid or sale prices (whichever is applicable) in the
over-the-counter market over the 20-day period ending three trading days prior to the closing of
the Fundamental transaction if the Common Stock is then actively traded in the over-the-counter
market, or the then most recently completed financing if the Common Stock is not then traded on a
securities exchange or in the over-the-counter market



TCorp = expiration date of Warrants to purchase shares of Common Stock



tCorp = date of public announcement of Fundamental Transaction



TCorp-tCorp = time until Warrant expiration, expressed in years



s = volatility = the annualized standard deviation of daily log-returns (using a 262-day
annualization factor) of the price of Common Stock on the securities exchange over a 20-day trading
period, determined by the Holders, that is within the 100-day trading period ending on the trading
day immediately after the public announcement of the Fundamental Transaction described in Section
9(d) if the Common Stock is then traded on such exchange, or the annualized standard deviation of
daily-log returns (using a 262-day annualization factor) of the closing bid or sale prices
(whichever is applicable) in the over-the-counter market over a 20-day trading period, determined
by the Holders, that is within the 100-day trading period ending on the trading day immediately
after the public announcement of the Fundamental Transaction if the Common Stock is then actively
traded in the over-the-counter market, or 0.6 (or 60%) if the Common Stock is not then traded on a
securities exchange or in the over-the-counter market.



N = cumulative normal distribution function



d1 = (ln(SCorp/KCorp) + (r-λ+s2/2)(TCorp-tCorp)) ÷
(sv(TCorp-tCorp))



ln = natural logarithm



λ = dividend rate on the Common Stock for the most recent 12-month period at the time of closing of
the Fundamental Transaction.



KCorp = strike price of warrant



r = annual yield, as reported by Bloomberg at time tCorp, of the United States Treasury security
measuring the nearest time TCorp



d2 = d1- sv(TCorp-tCorp)